ValiRx Plc

Type: Company
Name: ValiRx Plc
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

SMALL CAP MOVERS: Allocate Software investors boosted by HG Capital takeover

Takeover talk put healthcare IT firm Allocate Software on top of the small cap risers as it backed a £110million cash bid from private equity firm HGCapital.HG is offering 153.55p a share, a 35 per cent premium to its previous close and investors will ... [Published Mail Online UK - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

ValiRx CEO on upcoming trial

Dr Satu Vainikka, chief executive of ValiRx ( LON:VAL ), talks to Proactive Investors about the cancer drug group’s upcoming trial, having just received the go-ahead. The Phase I/II study is for VAL201, its lead compound on advanced prostate and other ... [Published Proactiveinvestors United Kingdom RSS feed - Oct 16 2014]
First reported Oct 14 2014 - Updated Oct 15 2014 - 1 reports

Market report: Burberry cautions on luxury market

UK markets continue to slide on Tuesday as gains across the mining sector are offset by gloomy corporate newsflow, led by upmarket fashion brands Burberry ( BRBY ) and Mulberry ( MUL:AIM ) , and from recruiter Michael Page ( MPI ) . The benchmark FTSE ... [Published Shares Magazine - Oct 14 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 3 reports

VALIRX : VAL201 Phase I/II Trial Ready To Begin Recruitment

LONDON ( Alliance News ) - ValiRx PLC said Tuesday that it can begin the recruitment of patients in its phase I/II trial of developmental prostate cancer treatment VAL201, following the completion of all ethical opinions and the required regulatory p ... [Published 4 Traders - Oct 14 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 2 reports

ValiRx's equity swap agreement with Yorkville comes to an end

ValiRx ( LON:VAL ) said its equity swap funding arrangement with Yorkville has been terminated early. The arrangement was entered into at the end of 2013 and has been exercised in full by agreement between the parties. Yorkville has sold 206.5mln ... [Published Proactiveinvestors United Kingdom RSS feed - Oct 08 2014]
First reported Oct 01 2014 - Updated Oct 01 2014 - 1 reports

Quarterly GuruScreen Review: Strategies under pressure as small cap indexes fall

By the end of last year small cap shares had surged so hard that many of us were left wondering whether prices had tipped into bubble territory. But rather than a sudden ‘pop’, the story so far in 2014 has been about a steady unwinding of that exuberance. ... [Published Stockopedia - Oct 01 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Proactive news summary including Andes Energia, Kibo Mining, Sirius Minerals, Tungsten Corp and Egdon Resources

Andes Energia ( LON:AEN ) has secured funding guarantees on three Colombian exploration blocks. The multi-layered deal also sees the reduction of its debt and gives the Latin America-focused oil group the option to bring on additional production. ... [Published Proactiveinvestors United Kingdom RSS feed - Sep 02 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 2 reports

Tuesday's most followed - Royal Mail, Quindell, Greka Drilling, Footsie and Redrow

As UK stocks were on the front foot, several stories were piquing interest on the online stage. One was from recently privatised Royal Mail ( LON:RMG ), which was the biggst loser on the premier exchange. Its shares fell 1.37% as news emerged that ... [Published Proactiveinvestors United Kingdom RSS feed - Sep 02 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 2 reports

ValiRx encouraged by efficacy data from lung cancer JV

ValiRx ’s ( LON:VAL ) joint venture with Tangent Reprofiling, ValiSeek, has received a boost from the preclinical efficacy studies on its lead lung cancer treatment.   The study on non-small cell lung cancers demonstrated at least a 50% reduction in ... [Published Proactiveinvestors United Kingdom RSS feed - Sep 02 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

ValiRx's interims show cash burn is not a worry, broker affirms

Interim results from ValiRx ( LON:VAL ) were broadly in line with expectations and show costs are under control, broker Daniel Stewart said. The group reported an operating loss for the first half of £1.1m, more or less in line with the expectations ... [Published Proactiveinvestors United Kingdom RSS feed - Aug 21 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 2 reports

|UPDATE - ValiRx gets MHRA approval for phase I/II cancer trial

-- adds broker target-- Shares is ValiRx ( LON:VAL ) shot higher as it confirmed Uk regulatory approval for a Phase I/II trial for its lead product that treats prostate cancer and other advanced solid tumours.  The trial will take place at University ... [Published Proactiveinvestors United Kingdom website - Aug 04 2014]
First reported May 15 2014 - Updated May 15 2014 - 2 reports

Proactive news summary: Antrim Energy, Caza, Fastjet, Galileo, Golden Saint, Kalibrate, Landore ...

Thursday was a day when Canadian listed and Canada-focused companies stormed the Proactive Investors universe. The recent strength in the nickel price is "fantastic" for Canada-focused mining firm Landore Resources ( LON:LND ), says its chief executive. ... [Published Proactiveinvestors United Kingdom RSS feed - May 15 2014]

Quotes

"This is a key moment for any drug-discovery company and I and all at ValiRx look forward to collecting the human experimental data and updating shareholders on our results and on our continued further progress" said Chief Executive Satu Vainikka in a statement
( "A Phase IPhase I II, dose escalation study to assess the safety and tolerability of VAL201 in patients with locally advanced or metastatic prostate cancer and other advanced solid tumours." )
"We appreciate Yorkville's flexibility and support to the company over the last year with respect to the management of working capital during this exciting period in ValiRx 's development" said Satu Vainikka, cbhief executive of the life science company, which has a focus on cancer diagnostics and therapeutics for personalised medicine...
"This adds commercial value and further enhances ValiRx 's portfolio of treatments for multiple cancer indications.”  "

More Content

All (32) | News (29) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Total Voting Rights [Published MoneyAM - 3 hours ago]
SMALL CAP MOVERS: Allocate Software investors b... [Published Mail Online UK - Oct 17 2014]
ValiRx CEO on upcoming trial [Published Proactiveinvestors United Kingdom RSS feed - Oct 16 2014]
Market report: Burberry cautions on luxury market [Published Shares Magazine - Oct 14 2014]
VALIRX : VAL201 Phase I/II Trial Ready To Begin... [Published 4 Traders - Oct 14 2014]
ValiRx PLC : Approved Clinical Trial Update [Published Investegate - Oct 14 2014]
ValiRx plc – Clinical Trial Update [Published Noodls - Oct 14 2014]
ValiRx's equity swap agreement with Yorkville c... [Published Proactiveinvestors United Kingdom RSS feed - Oct 08 2014]
ValiRx : Completes YA Global Master Equity Swap... [Published 4 Traders - Oct 08 2014]
Quarterly GuruScreen Review: Strategies under p... [Published Stockopedia - Oct 01 2014]
Proactive news summary including Andes Energia,... [Published Proactiveinvestors United Kingdom RSS feed - Sep 02 2014]
Tuesday's most followed - Royal Mail, Quindell,... [Published Proactiveinvestors United Kingdom RSS feed - Sep 02 2014]
Market movers: Egdon, Europa Oil, Greka Drillin... [Published Proactiveinvestors United Kingdom RSS feed - Sep 02 2014]
ValiRx encouraged by efficacy data from lung ca... [Published Proactiveinvestors United Kingdom RSS feed - Sep 02 2014]
ValiRx encouraged by preclinical results from l... [Published Proactiveinvestors United Kingdom website - Sep 02 2014]
ValiRx's interims show cash burn is not a worry... [Published Proactiveinvestors United Kingdom RSS feed - Aug 21 2014]
Tuesday's most followed: Just Eat, Serco, Prude... [Published Proactiveinvestors United Kingdom RSS feed - Aug 12 2014]
|UPDATE - ValiRx gets MHRA approval for phase I... [Published Proactiveinvestors United Kingdom website - Aug 04 2014]
ValiRx gets MHRA approval for phase I/II cancer... [Published Proactiveinvestors United Kingdom RSS feed - Aug 04 2014]
Broker spotlight: Stagecoach, ASOS, Sports Dire... [Published Proactiveinvestors United Kingdom website - Jun 10 2014]
ValiRx lead treatment moves to human stage canc... [Published Proactiveinvestors United Kingdom RSS feed - Jun 10 2014]
Proactive news summary: Antrim Energy, Caza, Fa... [Published Proactiveinvestors United Kingdom RSS feed - May 15 2014]
US equities continue their slide [Published Proactiveinvestors United Kingdom RSS feed - May 15 2014]
ValiRx pleased with new joint venture's early p... [Published BioPortfolio - May 15 2014]
ValiRx gets Japanese patent approval for NAV3 b... [Published BioPortfolio - May 01 2014]
UPDATE ValiRx sets up joint venture to advance... [Published BioPortfolio - Apr 08 2014]
UKs ValiRx forms joint venture to fast track lu... [Published BioPortfolio - Apr 08 2014]
Innovation Forum [Published TrustNet - Apr 08 2014]
Q&A ValiRx looks forward to clinical trials [Published BioPortfolio - Apr 01 2014]
ValiRx to carry out further stability and steri... [Published BioPortfolio - Apr 01 2014]
1 2
In Focus
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ValiRx encouraged by preclinical results from l... [Published Proactiveinvestors United Kingdom website - Sep 02 2014]
ValiRx ’s ( LON:VAL ) joint venture with Tangent Reprofiling, ValiSeek, has received a boost from the preclinical efficacy studies on its lead lung cancer treatment.   The study on non-small cell lung cancers demonstrated at least a 50% reduction in ...
|UPDATE - ValiRx gets MHRA approval for phase I... [Published Proactiveinvestors United Kingdom website - Aug 04 2014]
-- adds broker target-- Shares is ValiRx ( LON:VAL ) shot higher as it confirmed Uk regulatory approval for a Phase I/II trial for its lead product that treats prostate cancer and other advanced solid tumours.  The trial will take place at University ...
Broker spotlight: Stagecoach, ASOS, Sports Dire... [Published Proactiveinvestors United Kingdom website - Jun 10 2014]
You wait ages for a broker note on buses and train operators and two turn up at once. Deutsche Bank expects this year to continue to be dominated by rail re-franchising awards.  So far this year Thameslink has been awarded to Govia (from FirstGroup ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.